Cellyan officer files initial ownership Form 3

Cellyan Biotechnology Co., Ltd has an initial ownership report for Chief Strategy Officer Wang Zifeng under a Form 3 filing.

Rhea-AI Filing Summary

Cellyan Biotechnology Co., Ltd has an initial ownership report for Chief Strategy Officer Wang Zifeng under a Form 3 filing. The data shows no reported common stock or derivative holdings and no buy, sell, or other insider transactions associated with this officer in the reported period.

Key Terms

reportingPersons, Chief Strategy Officer, is_ten_percent_owner

3 terms

reportingPersons financial

""reportingPersons": [{"name": "Wang Zifeng""

Chief Strategy Officer financial

""officer_title": "Chief Strategy Officer""

A chief strategy officer (CSO) is the senior executive who crafts a company’s long-term plan and decides which markets, products, partnerships, or investments to prioritize—think of them as the company’s navigator plotting the course. Investors pay attention because the CSO shapes where the company will grow, what risks it will take, and how it will deploy resources; strong strategic direction can improve future revenue and value, while poor choices can weigh on returns.

is_ten_percent_owner financial

""is_ten_percent_owner": 0"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Cellyan Biotechnology (HKPD) Form 3 filing show for Wang Zifeng?

The Form 3 for Cellyan Biotechnology lists Chief Strategy Officer Wang Zifeng as a reporting person. It does not show any common stock or derivative positions and reports no insider transactions for this officer in the data provided.

Does Cellyan Biotechnology officer Wang Zifeng report any insider trades in this Form 3?

No insider trades are reported for Chief Strategy Officer Wang Zifeng in this Form 3. The transaction summary records zero buy, sell, exercise, gift, tax withholding, restructuring, or other transaction activity for the period covered.

Are there any derivative securities reported for Wang Zifeng in Cellyan Biotechnology’s Form 3?

No derivative securities are listed for Wang Zifeng in this Form 3. The derivative summary is empty, and the transaction summary shows zero derivative transactions or exercises associated with this reporting person.

What role does Wang Zifeng hold at Cellyan Biotechnology in this Form 3?

The Form 3 identifies Wang Zifeng as an officer of Cellyan Biotechnology, serving as Chief Strategy Officer. The filing also indicates that this officer is not classified as a ten percent beneficial owner in the company’s equity securities.

Does the Cellyan Biotechnology (HKPD) Form 3 indicate ten percent ownership for Wang Zifeng?

The Form 3 shows that Wang Zifeng is not a ten percent owner. The is_ten_percent_owner field is set to zero, indicating this reporting person does not meet the threshold for ten percent beneficial ownership in Cellyan Biotechnology.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/09/2026 - 10:22 AM EDT Learn about SEC filing dates

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Wang Zifeng

(Last) (First) (Middle)

RM 5102, INTERNATIONAL ARBITRATION BLDG

NANSHAN DISTRICT

(Street)

SHENZHEN CITY GUANGDONG PROVINCE 518052

(City) (State) (Zip)

CHINA

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
Cellyan Biotechnology Co., Ltd [ HKPD ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Strategy Officer

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

No securities are beneficially owned.

	/s/ Zifeng Wang	06/08/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)